Results 261 to 270 of about 369,336 (315)

Long‐term cardiovascular outcomes of immune checkpoint inhibitor‐related myocarditis: A large single‐centre analysis

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1237-1245, April 2025.
Abstract Aims Immune checkpoint inhibitors (ICI) are the cornerstone of modern oncology; however, side effects such as ICI‐related myocarditis (irM) can be fatal. Recently, Bonaca proposed criteria for irM; however, it is unknown if they correlate well with cardiovascular (CV) ICI‐related adverse events.
Lorenzo Braghieri   +12 more
wiley   +1 more source

Feasibility of Magnetic Resonance Imaging-Guided Pulmonary Artery Stenting in a Commercial Wide-Bore 0.55-T Scanner. [PDF]

open access: yesJACC Basic Transl Sci
Liu Y   +17 more
europepmc   +1 more source

Effects of sodium–glucose co‐transporter inhibitors on individual clinical endpoints and quality of life

open access: yesESC Heart Failure, Volume 12, Issue 2, Page 1271-1282, April 2025.
Effects of SGLTi on Individual Clinical Endpoints and Quality‐of‐Life: outcome from randomized data. Abstract Aims Sodium–glucose co‐transporter inhibitors (SGLTis) have cardiovascular protective effects. We aimed to assess the effects of SGLTis on individual hard clinical endpoints and quality of life (QoL) in patients with cardiovascular risk factors.
Jia Liao   +27 more
wiley   +1 more source

Prognostic value of right ventricular-pulmonary artery coupling in patients with muscular dystrophies. [PDF]

open access: yesSci Rep
Fayssoil A   +17 more
europepmc   +1 more source

Pulmonary Embolism or Pulmonary Artery Intimal Sarcoma? Diagnostic Pitfalls in a Rare Vascular Malignancy. [PDF]

open access: yesEur J Case Rep Intern Med
Natale R   +6 more
europepmc   +1 more source

Immediate Pulmonary Embolism or Pulmonary Artery Thrombosis Following Blunt Chest Injury? [PDF]

open access: yesEur J Case Rep Intern Med
Siddiqui T   +6 more
europepmc   +1 more source

Home - About - Disclaimer - Privacy